ATR-258
spec sheet7 rows
ATR-258 is an investigational, GRK2-biased beta2 adrenergic receptor agonist developed by the Swedish company Atrogi AB for type 2 diabetes and obesity [2]. It emerged from a 2025 Cell paper in which ligand-based virtual screening and chemical evolution produced GRK-biased adrenergic agonists, with compound 15 shown to drive insulin-independent glucose uptake while avoiding the Gs and beta-arrestin signaling that limit classical beta2 agonists [1]. The rationale rests on a decade of GRK2 biology: GRK2 upregulation and Gi-biased beta2AR signaling are linked to heart failure and metabolic dysregulation [5], and GRK2-biased transduction is now framed as a distinct therapeutic axis beyond G protein and arrestin signaling [3]. A 2026 perspective argues the biased agonist paradigm for diabetes and obesity is edging toward clinical reality [4]. Mechanism-context studies on GRK2 in beta-adrenergic signaling and blood pressure regulation support the class biology [6] [7]. Atrogi has advanced follow-on candidates into early human testing per company announcements, but no clinical results are published; the evidence base is preclinical.
- Insulin-independent glucose uptake in preclinical models
- Design avoids Gs-mediated cardiac signaling
- Design avoids arrestin-dependent desensitization
- Novel first-in-class mechanism with a landmark 2025 paper
- No clinical safety data published
- Beta2 agonism carries hemodynamic class concerns
- Investigational status with no regulatory review
evidence, by species7 cited papers
- ATR-258 targets GRK2, a kinase better known for its role in heart failure, as a metabolic drug target.
- Classical beta2 agonists failed as diabetes drugs because of cardiac Gs signaling; GRK bias is designed to avoid exactly that.
- The compound series was named in Cell 2025 after virtual screening and chemical evolution.
- Its developer, Atrogi AB, is a Stockholm University spinout.
- There is no PubMed record under the code ATR-258; the literature is indexed under Atrogi and the GRK2-biased mechanism.
Mechanism
The beta2 receptor mediates -independent glucose uptake in muscle, but classical beta2 agonists are poor diabetes candidates because Gs-mediated signaling drives cardiac side effects and beta-arrestin recruitment causes desensitization [1]. ATR-258 is designed as a biased that favors GRK2-mediated transduction over Gs and arrestin pathways, capturing the metabolic benefit while sidestepping the cardiac liability [1]. GRK2 itself is established as a causal node in heart failure, where its upregulation promotes Gi-biased beta2AR signaling [5], and GRK2-biased signaling is now described as a non-canonical transducer axis independent of G proteins and arrestins [3]. Related biased beta2AR/Gi/GRK2 pathway work in cardiac autoantibody models [6] and GRK2 knockdown studies in blood pressure regulation [7] illustrate the broader class biology. Atrogi's research program targets this pathway as an -independent route to glycemic control [2].
receptor fingerprint
Beta2 receptorbiased agonism favoring GRK2 transduction over Gs and beta-arrestin signaling
GRK2recruited as a non-canonical transducer of metabolic beta2AR signaling
-independent glucose disposalactivates muscle glucose uptake bypassing the failing insulin signaling pathway
nothing. with no native signal there is nothing to modulate, so a resting target stays resting; this is the property a direct agonist does not have.
Safetyrisks and cautions, not medical advice
No clinical safety data are published. The development rationale is explicitly safety-driven: avoiding Gs-mediated cardiac stimulation and arrestin-dependent desensitization is the point of GRK bias [1]. Because beta2 adrenergic receptors also regulate blood pressure and vascular tone, and GRK2 knockdown itself alters vascular reactivity [7], hemodynamic effects remain a plausible class concern that only human data can resolve. The compound is investigational and not available as a product.
Investigational: in development or trials, not approved for general use.
No clinical safety data are published. The development rationale is explicitly safety-driven: avoiding Gs-mediated cardiac stimulation and arrestin-dependent desensitization is the point of GRK bias [1]. Because beta2 adrenergic receptors also regulate blood pressure and vascular tone, and GRK2 knockdown itself alters vascular reactivity [7], hemodynamic effects remain a plausible class concern that only human data can resolve. The compound is investigational and not available as a product.
History
Atrogi AB, a Stockholm University spinout, developed the GRK2-bias concept as a non-insulin dependent approach to type 2 diabetes, with the strategy described in 2021 [2]. The field-defining preclinical milestone came in 2025, when a Cell paper reported GRK-biased adrenergic agonists for type 2 diabetes and obesity, including the compound series from which ATR-258 derives [1]. Reviews in 2025 and 2026 consolidated the GRK2-biased signaling framework and its clinical prospects [3] [4]. Atrogi reports first subjects dosed in a phase 1 program in 2026, but no results are in the literature.
Reputation
In the pharmacology community ATR-258 sits at the leading edge of biased GPCR drug design, cited as an example of going beyond G protein and arrestin bias to target GRK transduction itself [3]. The metabolic community views the GRK2-biased beta2 approach with cautious interest, since prior beta2-based diabetes candidates failed on cardiac grounds [1]. The compound has no consumer reputation: it is not marketed, and there is no supplement or nootropic presence.
Subjective profileweighing the evidence above
A scientifically elegant first-in-class mechanism with a landmark 2025 paper behind it, but no published efficacy or safety data; the GRK2-bias concept is the story so far, not the compound.
weighing the evidence aboveResources
This entry is here for reference.
Research
- 1.GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity.
- 2.A new approach to treat type 2 diabetes; targeting a non-insulin dependent pathway.
- 3.Beyond G protein and arrestin: GRK2-biased beta2AR signaling.
- 4.Biased agonists for the treatment of type 2 diabetes and obesity: a novel pharmacological paradigm edging closer to clinical reality?
- 5.Gi-biased beta2AR signaling links GRK2 upregulation to heart failure.
- 6.Biased activation of beta(2)-AR/Gi/GRK2 signal pathway attenuated beta(1)-AR sustained activation induced by beta(1)-adrenergic receptor autoantibody.
- 7.GRK2 targeted knock-down results in spontaneous hypertension, and altered vascular GPCR signaling.
7 listed here; entry last updated August 2026
Reviews
reviews are for members. make an account to read what people found and to leave your own! ^_^
My notesprivate to this device
FAQ4 questions
What is GRK2 bias?
Biased agonism normally means favoring G protein or arrestin signaling; GRK2 bias goes one step further and favors signaling through the receptor kinase GRK2 itself, which the 2025 Cell paper shows can deliver metabolic benefit without the cardiac side effects of classical beta2 agonists.
Is ATR-258 available to buy?
No. It is an investigational compound with no approved status, no marketed product and no consumer availability; any product sold under the name is not the Atrogi compound.
Why does it matter that beta2 agonists failed for diabetes before?
Older beta2 agonists activated Gs and arrestin pathways, causing cardiac stimulation and receptor desensitization. GRK-biased compounds aim to keep the glucose benefit while avoiding those two liabilities.
Has ATR-258 been tested in humans?
No results are published. The developer reported first subjects dosed in a phase 1 program in 2026, but there are no clinical data in the literature.